- This pioneering collaboration brings together GBU’s academic research strengths with the translation and commercialization experience of Cellimune Biotech
- CAR-T therapy is an excellent example of how modern biotechnology can serve society to address longstanding healthcare challenges such as blood cancer
- This collaboration is a significant step in contributing to India’s “Atmanirbhar Bharat” mission by developing cutting-edge therapies that directly benefit public health in
NE EDUCATION BUREAU
GANDHINAGAR, MAY 30
Gujarat Biotechnology University (GBU) has signed a Memorandum of Understanding (MoU) with Celliimune Biotech Pvt Ltd here on Friday to develop indigenous Chimeric Antigen Receptor T-cell (CAR-T) therapy for blood cancer patients.
The MoU signing ceremony was held under the chairmanship of Mona K. Khandhar IAS, Principal Secretary, Department of Science and Technology (DST), Gujarat; Ankur Vaid, Director, Cellimune Biotech and Sudhir Vaid, Chairman and Managing Director of Concord Biotech Limited at the GBU in Gandhinagar.
Ankur Vaid, Director of Celliimune Biotech, highlighted the crucial role of modern biotechnology-based industries such as Celliimune, as a foundation for future medicine to address healthcare challenges of the society.
“GBU is committed to supporting the development of biotechnology ecosystem in Gujarat, making GBU an epicenter of biotech revolution in India.” said Dr. Subeer S. Majumdar, Director General of GBU.
This agreement reflects the commitment of both the organizations to make cutting-edge cancer therapies accessible in India at affordable price. This collaboration is a major development wherein an academic institution and a biopharmaceutical company have entered into an agreement for the co-development of advanced CAR-T cell therapy for blood cancer.
CAR-T therapy is an excellent example of how modern biotechnology can serve society to address longstanding healthcare challenges such as blood cancer. It is a precision medicine approach where patient’s own immune cells (T cells) are genetically engineered to make it capable of fighting effectively against cancer. Future scientific advancement of this approach may also address other types of cancer.
GBU was established under the Department of Science and Technology (DST), Government of Gujarat, to drive world-class biotechnology education and translational research. On the other hand, Celliimune Biotech Limited is focused on improving patient’s lives through cell & gene therapy. It is backed by Ankur Vaid who is also promoter of Concord Biotech Ltd. which is a globally recognized biopharmaceutical giant and also by Dr. Govind Chavada (Neurologist), a Glasgow based Indian diaspora.
This pioneering collaboration brings together GBU’s academic research strengths with the translation and commercialization experience of Cellimune Biotech. This collaboration is a significant step in contributing to India’s “Atmanirbhar Bharat” mission by developing cutting-edge therapies that directly benefit public health in India.
